AUTHORS
Amanda Kofides, MSc, Xia Liu, MD2, Hao Sun, MD, PhD3, Nickolas Tsakmaklis4, Maria Luisa Guerrera, MD5, Christopher Patterson, MBA, MPH6, Shayna Sarosiek, MD7, Jorge J Castillo, MD8, Zachary R Hunter, PhD9, Steven Treon, MD, PhD10, Shirong Liu, PhD11
AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Introduction: The highly prevalent MYD88 L265P mutation drives malignant growth via NF-κB activation through Bruton tyrosine kinase (BTK) in Waldenström macroglobulinemia (WM) (Yang et al, Blood 2013; 122(7):1222-1232), underpinning the clinical use of BTK inhibitors in WM (Treon et al, NEJM 2015; 372(15):1430-1440). Copy number alteration studies have identified a common 6q deletion (del6q) in WM patients that affects regulators of MYD88 signaling, including IBTK. IBTK copy number loss occurs in up to half of MYD88-mutated lymphoma patients (Guerrera et al, Haematol. 2018; 103(9):e408-e411). Homozygous del6q with loss of IBTK expression has been observed in ibrutinib resistant WM patients (Jimenez et al, Br. J. Haematol. 2020; 189(6):1165-1170). IBTK binds to the PH domain of BTK, thereby downregulating its activity, calcium mobilization, and NF-κB activation (Liu et al, Nat. Immunol. 2(10):939-946). However, the role of IBTK in MYD88-mutated B-cell malignancies remains to be defined. We therefore investigated the functional role of IBTK in MYD88 mutated lymphomas.
Methods: IBTK isoforms were identified by whole exome sequencing. IBTK protein levels were assessed by western blot in MYD88-mutated and wild-type (WT) cell lines and in sorted CD19+ B cells from WM patients. Single-cell RNA sequencing with BCR sequencing was used to compare IBTK transcript levels between malignant and non-malignant B cells, and between del6q and 6q-intact cells. IBTK was overexpressed in MYD88-mutated (BCWM.1, MWCL-1, TMD8, HBL-1) and WT (OCI-Ly7, OCI-Ly19, Ramos, RPMI-8226) lines to identify interacting partners via pull-down assays and mass spectrometry phospho-proteomics. RNA-seq was performed to characterize signaling pathway changes in IBTKγ-overexpressing versus vector-control cells.
Results: Single-cell analysis of WM patients showed increased IBTK transcription in malignant versus non-tumor B cells, except in del6q cases. Of the IBTK isoforms (α, β, γ), only α and γ were expressed, with IBTKγ showing heterogeneous expression. IBTKα was consistently expressed across WM patients and MYD88-mutated lines regardless of del6q or treatment status, whereas IBTKγ was reduced in a subset of WM patients. Although both IBTKα and IBTKγ have been reported to bind and inactivate BTK (Janda et al. Blood 2011; 117(24):6520-6531), no investigation has been undertaken in MYD88-mutated lymphomas. Unexpectedly, IBTKγ overexpression did not alter BTK activation, and pull-down assays in BCWM.1 and TMD8 cells showed that IBTKγ does not bind BTK; instead, BCLAF1 emerged as its dominant binding partner. HCK activity appeared to suppress this interaction: covalent (zanubrutinib) or non-covalent (pirtobrutinib) BTK inhibition did not affect IBTKγ–BCLAF1 binding, while the BTK/HCK dual inhibitor KIN-8194 enhanced it. IBTKγ overexpression produced two distinct signaling effects: increased inflammatory pathway activity, including elevated IκBα phosphorylation, alongside decreased PLCγ2 and PKC phosphorylation, the latter likely downstream of BCLAF1. Consequently, IBTKγ overexpression induced apoptosis, which was enhanced by the BCL2 inhibitor venetoclax as well as the JAK2 inhibitor pacritinib, but unaffected by use of BTK-inhibitors.
Conclusions: IBTKγ plays a distinct, BTK-independent signaling role in MYD88 mutated lymphomas, combining proinflammatory IκBα activation with suppression of PLCγ2/PKC signaling via BCLAF1 interaction to drive apoptosis. These findings provide novel mechanistic insights to explain BTKi resistance in del6q WM patients and provides a framework for targeting IBTKγ in MYD88 driven lymphomas.
DISCLOSURES
Amanda Kofides, MSc: No relevant conflicts of interest to declare.